Home · Health · Sep 29 archive
Triple Therapy Shows Promise for Asthma Remission
Developing
In Short: A study suggests adding a long-acting muscarinic antagonist to dual inhaler therapy improves asthma remission rates.
A new study indicates that adding a long-acting muscarinic antagonist (LAMA) to the existing dual therapy of inhaled corticosteroids (ICS) and long-acting beta-2 agonists (LABA) can increase the chances of achieving clinical remission in patients with moderate-to-severe asthma.
Researchers found that optimizing inhaler technique and adherence to the dual therapy first, followed by the addition of a LAMA, can lead to better outcomes.
The study, which was published in a medical journal, emphasizes the importance of enhancing current asthma management strategies before considering more advanced treatments like biologics.
However, the study's follow-up period of only 52 weeks is noted as a limitation, as a longer-term evaluation would provide a more comprehensive understanding of the therapy's effectiveness.
What's still developing
- "These data demonstrate that clinical remission can be achieved in patients with asthma that is uncontrolled by ICS/LABA through the optimisation ( i.e. adherence and improved inhaler technique) of the inhaled therapy, and that the proportion achieving clinical remission can be increased by the addition of a LAMA in the form of BDP/FF/G. This supports the recommendation to optimise inhaled asthma treatment prior to escalating to biologic therapies," the authors wrote.